In 2022, the UK Government published the Women’s Health Strategy for England, the first government-led strategy of its kind focused on the health experiences of women and girls.
Its opening statement was to the point:
“Women have told us that they are not listened to. They feel that their voices are dismissed and ignored when they seek help.”
Women’s Health Strategy for England, July 2022
The report described “deeply rooted” issues across the healthcare system, including fragmented services, delayed diagnoses and inconsistent experiences depending on geography, ethnicity and socioeconomic background.
Nearly four years later, it’s fair to say the conversation around women’s health has shifted. Menopause is discussed more openly in workplaces and parliament, endometriosis is receiving greater public attention, and Women’s Health Hubs are being expanded across England to create more joined-up local care.
In April 2026, the Government announced a renewed commitment to the strategy, stating that its next phase would focus on “turning commitments into action”.
Why does that wording matter? Because awareness was never supposed to be the end goal, it was the starting point.
The challenge facing the NHS now is implementation
Awareness alone does not redesign healthcare experiences. It does not shorten the average time to endometriosis diagnosis or help women navigate fragmented pathways between primary care, specialist services and community support. And it certainly does not create more time in a ten-minute consultation.
The strategy itself acknowledges this, with one of its central ambitions focused on “improving how the healthcare system listens to women.”
Listening “better” sounds simple but in reality, it means:
This is where pharma’s role becomes particularly important
The next era of women’s health is unlikely to be defined by awareness alone, but by the practical support that helps translate priorities into day-to-day improvements in care.
Endometriosis is perhaps one of the clearest examples of the need for a shift from awareness to implementation.
Public awareness of the condition has grown significantly in recent years, helped by campaigning, media attention and increasing openness around women’s health. Yet despite this progress, the average time to diagnosis in England remains close to nine years according to NHS England and Endometriosis UK data.
In that context, another awareness campaign alone is unlikely to solve the underlying challenge.
The greater opportunity lies in supporting better recognition and conversations much earlier in the patient journey. That could mean creating tools that help primary care teams identify when recurring presentations may indicate endometriosis rather than isolated symptoms or designing consultation frameworks that surface the cumulative impact of pain, fatigue and cycle disruption more clearly within time-pressured appointments.
In an overstretched NHS system, even small reductions in diagnostic friction can have meaningful impact on patient experience and time to diagnosis.
That is not awareness for awareness’ sake, it is implementation support.
There is also growing scrutiny around performative participation in women’s health. Audiences are becoming more sensitive to campaigns that join the conversation without meaningfully contributing to progress. The NHS strategy itself warns against reducing women’s health experiences to isolated conditions, rather than considering “women’s experiences of the healthcare system as a whole.”
That distinction is important because women do not experience healthcare in campaigns. They experience it in waiting rooms, rushed consultations, referral pathways and difficult decisions, or alone without any support or meaningful conversations at all.
The brands that will build long-term credibility in this space are will not be the ones producing the most content, they will be the ones demonstrating genuine understanding of the pressures facing both patients and healthcare professionals, and creating support that feels useful within the realities of NHS care.
The NHS Women’s Health Strategy opened the door to a long-overdue national conversation. The renewed 2026 commitment suggests that conversation is now entering its next phase: delivery.
For pharma marketers, medical affairs teams and healthcare communicators, that presents a challenge worth embracing.
Not:
“How do we create more awareness?”
But:
“How do we help awareness translate into action?”
Because women’s health does not need another awareness campaign, it needs support that helps change become tangible.
Sources
